- Abstract:
-
BACKGROUND
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
METHODS
In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Publisher:
- Massachusetts Medical Society Publisher's website
- Journal:
- New England Journal of Medicine Journal website
- Publication date:
- 2020-07-17
- Acceptance date:
- 2020-07-14
- DOI:
- EISSN:
-
1533-4406
- ISSN:
-
0028-4793
- Pubs id:
-
1118880
- Local pid:
- pubs:1118880
- Language:
- English
- Keywords:
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- 2020
- Rights statement:
- © 2020 Massachusetts Medical Society. All rights reserved.
- Notes:
- This is the publisher's version of the article. The final version is available online from Massachusetts Medical Society at: https://doi.org/10.1056/NEJMoa2021436
Journal article
Dexamethasone in hospitalized patients with Covid-19 — preliminary report
Actions
Authors
Funding
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record